Vestibulotoxicity in a patient without renal failure after inhaled tobramycin

Publication date: Available online 19 March 2019Source: American Journal of OtolaryngologyAuthor(s): Adam C. Kaufman, Steven J. EliadesAbstractAminoglycoside antibiotics have a long history of use in the control of gram-negative bacterial infections, but their systemic use has been complicated by known ototoxicity and nephrotoxicity. Because of the utility of these medications in patients with frequent pulmonary infections, there has been a move towards the use of inhaled agents, in particular tobramycin, due to a lower rate of systemic complications. Inhaled tobramycin is generally consider to be safe from otologic complications, with only two previous reports of ototoxicity, both in patients who had underlying chronic renal disease. Here we present the first case of a patient developing isolated vestibular toxicity, without associated hearing loss or evidence of renal insufficiency, in a patient receiving inhaled tobramycin. This is an extremely rare complication of an inhaled aminoglycoside and underscores the importance of careful monitoring despite perceived safety.
Source: American Journal of Otolaryngology - Category: Endocrinology Source Type: research